Detailed Information

Cited 20 time in webofscience Cited 20 time in scopus
Metadata Downloads

Multicenter phase. trial of modified FOLFIRINOX in gemcitabine-refractory pancreatic canceropen access

Authors
Chung, Moon JaeKang, HuapyongKim, Ho GakHyun, Jong JinLee, Jun KyuLee, Kwang HyuckNoh, Myung HwanKang, Dae HwanLee, Sang HyubBang, Seungmin
Issue Date
15-Dec-2018
Publisher
BAISHIDENG PUBLISHING GROUP INC
Keywords
Pancreatic cancer; FOLFIRINOX; Clinical Trial , Phase; Chemotherapy; Gemcitabine refractory
Citation
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, v.10, no.12, pp.505 - 515
Indexed
SCIE
SCOPUS
Journal Title
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
Volume
10
Number
12
Start Page
505
End Page
515
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/2819
DOI
10.4251/wjgo.v10.i12.505
ISSN
1948-5204
Abstract
AIM To evaluate the efficacy and safety of modified FOLFIRINOX as a second-line treatment for gemcitabine (GEM)-refractory unresectable pancreatic cancer (PC). METHODS This study was a prospective, multicenter, one-arm, open-label, phase. trial. Patients with unresectable PC, who showed disease progression during GEM-based chemotherapy were enrolled. All patients were administered FOLFIRINOX with reduced irinotecan and oxaliplatin (RIO; irinotecan 120 mg/m(2) and oxaliplatin 60 mg/m(2)), which was set according to the phase. study of FOLFIRINOX. The objective response rate (ORR), disease control rate (DCR), progressionfree survival (PFS), overall survival (OS), adverse events were evaluated. Additionally, changes in quality of life (QoL) were assessed using a questionnaire on QoL. RESULTS Between August 2015 and May 2016, a total of 48 patients were enrolled. The median follow-up time was 259 d with a median of 8.5 cycles. The ORR and DCR were 18.8% and 62.5%, respectively, including one patient who showed complete remission. The median PFS was 5.8 mo [ 95% confidence interval (CI): 3.7-7.9] and median OS was 9.0 mo (95% CI: 6.4-11.6). Neutropenia (64.6%) was the most common grade 3-4 adverse event, followed by febrile neutropenia (16.7%). Although 14.6% of patients experienced grade 3 fatigue, most non-hematologic AEs were under grade 2. In the QoL analysis, the global health status score before treatment was not different from the score at the last visit after treatment (45.43 +/- 22.88 vs 48.66 +/- 24.14, P = 0.548). CONCLUSION FOLFIRINOX with RIO showed acceptable toxicity and promising efficacy for GEM-refractory unresectable PC. However, this treatment requires careful observation of treatment-related hematologic toxicities.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Hyun, Jong Jin photo

Hyun, Jong Jin
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE